(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's shares are expected to trade on a split adjusted basis beginning February 10, 2025.

Holdings announced the date of effectiveness and the ratio of a forthcoming reverse stock split of the Company’s Common Stock. On January 13, 2025, the Company announced, on a Current Report on Form 8-K,

On January 14, 2025, the Board approved a one-for-two-hundred (1:200) Reverse Split of the Common Stock. The Company anticipates that beginning with the opening of trading on February 10, 2025, the Company’s Common Stock will trade on the Nasdaq Capital Market on a split-adjusted basis and will have a new CUSIP number, 829322502.

Introduction - Issuers listed on the Nasdaq Stock Market and the New York Stock Exchange (NYSE) often conduct reverse stock splits to

Focus Universal inc. (Nasdaq:FCUV) (”Focus” or the “Company”), a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G, announces that its board of

Algorhythm Holdings, Inc. (NASDAQ:RIME), a Delaware-incorporated company specializing in phonograph records and prerecorded audio tapes and disks, announced today a significant change to its capital structure.